文献速递细胞病理与分子病理血液淋巴病理

游离DNA在分子病理学中的价值

The value of cell-free DNA for molecular pathology.
PubMed 文献 · J Pathol · 2018-03-12

本文综述游离核酸作为分子病理分析物的优势,重点讨论循环肿瘤DNA(ctDNA)可反映原发瘤与转移灶基因组改变、支持多次采样监测治疗反应与耐药。文章还涵盖血浆、尿液和脑脊液等体液中游离核酸的临床应用及分析前因素与监管要求。

要点

  • ctDNA可非侵入性反映原发瘤与转移灶的基因组改变
  • 多次采样ctDNA可监测治疗反应、基因组演化、耐药与微小残留病
  • 已有临床ctDNA检测获批用于指导治疗

核心结论

  • 游离核酸是分子病理学中日益重要的非侵入性分析物,ctDNA检测已开始进入肿瘤临床实践。

研究设计与样本

  • 综述,讨论游离核酸在不同体液中的优势及其在实体瘤和血液恶性肿瘤中的临床应用。

主要发现

  • ctDNA的基因组改变谱可反映原发肿瘤和远处转移灶。
  • ctDNA可多次采样,克服单次活检分析的局限性。
  • 定期采样ctDNA可用于监测治疗反应、界定肿瘤基因组演化、评估耐药获得与微小残留病。
  • 近期已有临床ctDNA检测获批用于指导治疗。

临床怎么用

  • 可将游离核酸检测用于非侵入性肿瘤基因组分析及纵向监测。
  • 临床部署需考虑分析前因素和监管要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of cancer. The technological advances in tissue profiling have also been applied to the study of cell-free nucleic acids, an area of increasing interest for molecular pathology. Cell-free nucleic acids are released from tumour cells into the surrounding body fluids and can be assayed non-invasively. The repertoire of genomic alterations in circulating tumour DNA (ctDNA) is reflective of both primary tumours and distant metastatic sites, and ctDNA can be sampled multiple times, thereby overcoming the limitations of the analysis of single biopsies. Furthermore, ctDNA can be sampled regularly to monitor response to treatment, to define the evolution of the tumour genome, and to assess the acquisition of resistance and minimal residual disease. Recently, clinical ctDNA assays have been approved for guidance of therapy, which is an exciting first step in translating cell-free nucleic acid research tests into clinical use for oncology. In this review, we discuss the advantages of cell-free nucleic acids as analytes in different body fluids, including blood plasma, urine, and cerebrospinal fluid, and their clinical applications in solid tumours and haematological malignancies. We will also discuss practical considerations for clinical deployment, such as preanalytical factors and regulatory requirements. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Stewart CM, Kothari PD, Mouliere F, et al. The value of cell-free DNA for molecular pathology. J Pathol. 2018. PMID: 29380875. doi:10.1002/path.5048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。